Sun Pharmaceutical Industries Limited has released its Sustainability Report for the financial year 2024-25, detailing its Environment, Social, and Governance (ESG) performance. The report, which covers 79% of the company's operating sites, aligns with global frameworks such as GRI Standards 2021, UN Global Compact principles, and TCFD recommendations. Key highlights for FY25 include a 21% reduction in absolute Scope 1 and Scope 2 carbon emissions compared to the 2020 baseline, with a target of 35% reduction by 2030. Renewable energy accounted for approximately 41% of the total energy mix. The company also achieved a 25% reduction in absolute water consumption against the 2020 baseline, surpassing its 2025 target and aiming to be water-positive by 2030. On the social front, Sun Pharma invested ₹1,424 Million in CSR initiatives, impacting approximately 4.47 million lives across India. The company aims for 30% representation of women in its workforce by 2040. Governance highlights include 62.5% independent Board Directors and an average Board meeting attendance of 92.9% across 7 Board meetings held during the reporting year. The report also details the company's R&D investments, which amounted to ₹32.48 billion (~6.2% of sales), focusing on developing innovative and quality medicines. Sun Pharma's global presence spans approximately 100 countries, with revenues exceeding $6.2 billion.
